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Abstract: While half of all human tumors possess p53 mutations, inactivation of wild‐type p53 can also occur through a
variety of mechanisms that do not involve p53 gene mutation or deletion. Our laboratory has been interested in tumor
cells possessing wild‐type p53 protein and elevated levels of HdmX and/or Hdm2, two critical negative regulators of p53
function. In this study we utilized RNAi to knockdown HdmX or Hdm2 in MCF7 human breast cancer cells, which harbor
wild‐type p53 and elevated levels of HdmX and Hdm2 then examined gene expression changes and effects on cell growth.
Cell cycle and growth assays confirmed that the loss of either HdmX or Hdm2 led to a significant growth inhibition and G1
cell cycle arrest. Although the removal of overexpressed HdmX/2 appears limited to an anti‐proliferative effect in MCF7
cells, the loss of HdmX and/or Hdm2 enhanced cytotoxicity in these same cells exposed to DNA damage. Through the use
of Affymetrix GeneChips and subsequent RT‐qPCR validations, we uncovered a subset of anti‐proliferative p53 target genes
activated upon HdmX/2 knockdown. Interestingly, a second set of genes, normally transactivated by E2F1 as cells
transverse the G1‐S phase boundary, were found repressed in a p21‐dependent manner following HdmX/2 knockdown.
Taken together, these results provide novel insights into the reactivation of p53 in cells overexpressing HdmX and Hdm2.

INTRODUCTION

network of proteins, and is critical for maintaining
genomic stability and suppressing tumor formation.

Only half of all human tumors contain mutations in the
p53 tumor suppressor gene [1], with the other half
retaining wild-type p53 but possessing defects in the
expression of p53 regulatory proteins and pathways.
Under non-stress conditions, p53 protein is maintained
at a low basal level by constant ubiquitination and
proteasomal degradation [2]. Upon DNA damage or
various types of cellular stress, p53 is stabilized and
functions as a transcription factor to induce genes
involved in cell cycle arrest, apoptosis, and DNA repair
[3]. The stringent regulation of p53 involves a complex
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Hdm2 and its structural homologue HdmX represent
two essential negative regulators of p53 as
demonstrated by their embryonic lethality in knockout
mice and subsequent rescue by concurrent elimination
of p53 [4]. Hdm2 inactivates p53 function through
direct association resulting in an inhibition of
transactivation [5] and, through its E3 ligase activity
targeting p53, by ubiquitin-mediated proteasome
degradation [6, 7]. While HdmX shows conservation in
the Hdm2 E3 ligase ring finger domain through which it
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can heterodimerize with Hdm2 [8, 9], HdmX lacks the
ability to ubiquitinate p53 in vivo [10, 11] and thus can
only antagonize p53 transactivation [12]. The
heterodimerization of Hdm2 and HdmX also plays a
critical role in the response to DNA damage enabling
Hdm2 to promote the ubiquitination and rapid
proteasomal degradation of HdmX, thereby facilitating
the tumor suppressor activity of p53 [13-15]. Thus, the
interactions between p53, Hdm2 and HdmX are critical
for complete regulation of p53 [4].

RESULTS
RNAi knockdown of Hdm2 and HdmX in MCF7
cells
Given that HdmX and Hdm2 are overexpressed in
approximately 17% of human tumors [16] the majority
of which possess wild-type p53, this study set out to
examine how loss of Hdm2/X affected gene expression
and tumor cell growth. MCF7, which possess wild-type
p53 [25] and elevated levels of both HdmX and Hdm2
(Figure 1A) was the tumor cell line used in these
studies. To inactivate HdmX and Hdm2 we employed
siRNA targeting each gene as described in the materials
and methods.

The overexpression of either Hdm2 or HdmX can
inhibit the activity of p53 and directly contribute to
tumor formation. It is not surprising that either one or
both proteins are found overexpressed in many human
tumors and tumor cell lines which harbor wild-type p53
[16]. Diverse approaches to activate the wild-type p53
in these tumors include the use of small molecule
antagonists like Nutlin to inhibit the Hdm2-p53
interaction [17-19], and the use of antisense
oligonucleotides, antibodies, and small interfering
RNAs directed at Hdm2 or HdmX [20-23]. Recent
findings suggest that Hdm2 and HdmX are specific
independent therapeutic targets for activating wild-type
p53 and that anti-cancer approaches that target both
Hdm2 and HdmX should be considered as a means of
treatment for tumors [16, 18, 24].

Before performing the Affymetrix GeneChip
experiments we developed a triple transfection protocol
that led to over 90% of the MCF7 cells taking up the
siRNA (data not shown). Next, the effectiveness of the
knockdown was assessed using RT-qPCR (data not
shown) and Western blotting. Following the triple
transfection protocol HdmX and p53 protein levels were
undetectable with Hdm2 showing a greater than 80%
reduction in protein expression (Figure 1B). As
expected, the loss of either HdmX or Hdm2 led to an
increase in the levels of p21. This p21 increase is p53dependent since no increase in p21 protein levels was
detected upon concurrent knockdown of HdmX and
p53. While it has been suggested that Hdm2 controls
the levels of p53 in non-stressed cells [26, 27], in our
hands MCF7 cells showed only a slight increase in p53
protein levels following the combined loss of HdmX
and Hdm2. The inability of Hdm2 knockdown to result
in an increase in p53 protein could be the result of
MCF7 cells harboring an elevated level of HdmX.
Consistent with this suggestion, the treatment of MCF7
cells with Nutlin leads to increased p53 protein levels
through loss of Hdm2 binding to p53 and concurrent
Hdm2 mediated degradation of HdmX [28].

This study undertook an examination of gene
expression alterations and the biological effects
resulting from RNAi silencing of HdmX and Hdm2 in a
breast cancer cell line overexpressing both proteins.
Unlike previous studies examining only the biological
effect of either HdmX or Hdm2 loss, this study focuses
on a cell line where both proteins are overexpressed and
further compliments those previous studies with a
systematic examination of gene expression changes
following loss of HdmX or Hdm2. Interestingly, only
p53 target genes primarily associated with cell cycle
arrest were induced. More striking was the repression
of a large group of E2F-regulated genes upon HdmX/2
knockdown. Using siRNA approaches targeting p21,
we were able to show that these E2F-regulated genes
were repressed through p53 activation of p21.
Furthermore, cell proliferation and colony formation
assays confirmed that loss of HdmX or Hdm2 inhibited
tumor cell growth and could sensitize these cells to
treatment with doxorubicin. Taken together, these
results suggest that in cells where both Hdm2 and
HdmX are overexpressed, removal of one leads to an
anti-proliferative effect in tumor cells harboring wildtype p53 and induction of p53 cell cycle arrest genes
that negatively feedback onto the E2F pathway.
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Loss of Hdm2 and HdmX triggers inhibition of cell
growth
Other groups have reported that in cells where wild-type
p53 is kept in check by overexpression of HdmX or
Hdm2, their inhibition can trigger alterations in cell
growth [29] and in some conditions apoptosis [30]. To
assess the growth properties of RNAi knockdown of
p53 regulators Hdm2 and HdmX, siRNA-transfected
MCF7 cells were plated at low density in 6 well plates
and allowed to grow for an additional 10 days. While
transfection of siCon or sip53 resulted in only minimal
changes in cell growth (Figure 2B), knockdown of either
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Figure 1. (A) RT‐PCR analysis of hdmX and hdm2 gene expression in various human cell lines. The endogenous levels of hdmX and hdm2
were determined relative to H1299 cells. All samples were normalized to GAPDH. (B) RNAi knockdown of HdmX or Hdm2 triggers p53‐
dependent p21 induction. Western blot analysis of indicated proteins from the various siRNA or doxorubicin (Dox) treated MCF7 cells.
Knockdowns of the indicated proteins were greater than 80%. Protein extracts were made 24 hours after the last siRNA transfection or
treatment with 5 μg/ml doxorubicin.

decrease in colony formation correlated with an increase
in G1 arrest and not apoptosis (i.e. sub-G1) as
determined by flow cytometry (data not shown).

HdmX or Hdm2, alone or in combination led to
significantly fewer colonies (Figure 2A) and suppressed
cell growth when compared to siCon (Figure 2B). This
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both HdmX and Hdm2 led to the greatest level of
chemosensitivity (Figure 3A).
Enhanced chemosensitivity was also observed in cisplatin treatment of
siHdmX or siHdm2 MCF7 cells (data not shown).
Gene expression profiles of MCF7 cells lacking
HdmX or Hdm2
Having established an effective knockdown approach
with effects on cell growth and increased sensitivity to
DNA damage, we performed an Affymetrix GeneChip
experiment to assess how loss of HdmX or Hdm2
affected global gene expression in MCF7 cells. Each
RNAi transfection was performed in three separate biological replicates. The data analysis was carried out
using GeneSpring GX software. Given the similarity of
biological function uncovered in the previous experiments we focused our informatics on genes commonly
altered following RNAi treatment with siHdmX or
siHdm2. In summary, .cel files were normalized using
GCRMA, genes filtered by ANOVA and fold change,
and genes significantly altered by both siHdmX and
siHdm2 but not siHdmX + sip53 identified (see materials
and methods for detailed approach). From this approach
we uncovered 394 gene alterations common to
knockdown of both siHdmX and siHdm2 (Table 1).
p53 activation following loss of HdmX or Hdm2
triggers growth repressive genes

Figure 2. Loss of HdmX and/or Hdm2 inhibits MCF7
colony formation. (A) Following siRNA transfections, MCF7
cells were seeded at 500 cells/well in 6‐well plates. The cells
were allowed to grow for ten days then the colonies were
stained with crystal violet. Significantly fewer colonies were
present following knockdown of HdmX and/or Hdm2. The cells
transfected with sip53 or a non‐targeting control (siCon)
showed minimal effects on colony formation relative to non‐
transfected control (Con/Control). (B) The percent cell growth
relative to untransfected control was determined by extracting
the stain in 10% acetic acid and quantifying the stain by
reading absorbance at 590 nm.

The initial examination of the 394 genes focused on
those genes (n=222) that were increased following
siHdmX or siHdm2 treatment relative to siCon.
Thirteen genes were identified that were known p53regulated genes (Figure 4). As expected these genes
increased with siHdmX or siHdm2 treatment but had
expression levels comparable or lower than siCon when
treated with siHdmX+sip53 or sip53. Interestingly,
with the exception of Fas, this list of p53 target genes
consisted predominately of genes encoding proteins
involved in cell cycle arrest or DNA repair. Consistent
with a model whereby p53 proapoptotic target genes
require p53 that is phosphorylated at serine 46 by
HIPK2 [33-35], we observed no detectable
phosphorylation at serines 6, 15, 20, 46, or 392
following the RNAi transfection protocol employed in
these studies (data not shown).

Loss of HdmX or Hdm2 sensitizes MCF7 cells to
DNA damage
Several recent studies using Nutlin and various DNA
damaging agents reported that blocking Mdm2:p53
association led to increased chemosensitivity to DNA
damaging agents [31, 32]. To examine whether
knockdown of HdmX and Hdm2 can also elicit
increased cytotoxicity to DNA damage, MCF7 cells
were transfected with the indicated siRNA leading to
alterations of gene expression (Figure 3B). Cells were
then treated with varying doses of doxorubicin and cell
viability assessed. siRNAs targeting HdmX or Hdm2
increased doxorubicin cytotoxicity, while removing
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To confirm these results, we performed RT-qPCR using
TaqMan primers targeting five known p53 target genes,
three of which were identified in our analysis. p21,
BTG2 and ACTA2 are p53 target genes that are
associated with cell cycle arrest or growth inhibition
[36-38], while Hdm2 is a negative regulator of p53 and
Noxa a pro-apoptotic factor not observed in our list of
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known that p21 can inhibit CDK/cyclins involved in Rb
phosphorylation [40] and within the literature we
initially uncovered two reports where p53 activation led
to repression of TERT or Chk2, two known E2Fregulated genes [41, 42]. To determine whether
repression of these genes was the result of an HdmX or
Hdm2-dependent p53 activation, MCF7 cells were
treated with siHdm2 or siHdmX alone or in
combination with sip21. RNA was isolated and RTqPCR performed to monitor relative expression of
cyclin A2 (CCNA2), p21 and E2F1. While E2F1 did
not make the 394 gene list, it possesses an E2F1 DNA
binding site [43]. Relative expression for each of the
genes was normalized to GAPDH. As expected, loss of
HdmX or Hdm2 led to an increase in p21 and
Figure 3. Knockdown of HdmX enhances doxorubicin‐induced cytotoxicity. (A) Percent cell viability relative to untransfected
untreated control cells. MCF7 cells were treated with doxorubicin (0.25‐1.0 μg/mL) for 48 hours and cell viability was determined by
absorbance at 590 nm. The loss of HdmX and/or Hdm2 showed an enhanced cytotoxicity relative to control cells. (B) RT‐qPCR analysis of
hdmX, hdm2, p21 and p53 gene expression in the indicated siRNA transfected MCF7 cells. The hdmX, hdm2, and p53 transcripts were
effectively knocked down by siRNA prior to drug treatment.

concomitant decrease in both CCNA2 and E2F1 (Figure
7). In contrast, loss of Hdm2/X and p21 completely
abrogated CCNA2 and E2F1 repression consistent with
p53 activation inactivating E2F1 transactivation via p21
induction.

altered genes [39]. MCF7 cells were either mock
transfected (Mock), transfected with siRNA that does
not target any human gene (siCon) or transfected with
siRNA to HdmX or Hdm2 either alone or in
combination. The results in Figure 5 demonstrate that
relative to siCon, knockdown of HdmX led to
significant increases in hdm2, p21, BTG2 and ACTA2
gene expression.
No significant change in gene
expression was observed with Noxa, which is consistent
with our GeneChip results. With the obvious exception
of hdm2, siRNA-targeting Hdm2 led to similar
alterations in gene expression (Figure 5). Finally, when
both HdmX and Hdm2 were eliminated, the levels of
the cell cycle arrest genes p21, BTG2 and ACTA2
increased either synergistically or additively while
levels of Noxa remained unchanged. These results
validate our GeneChip data that p53-target genes were
induced upon HdmX or Hdm2 knockdown and that
several of these genes encode proteins involved in the
cell cycle arrest.
p53 upregulation of p21 leads to global repression of
E2F regulated genes
After searching for genes that were directly upregulated
by p53 we next evaluated those genes that were
repressed (N=172) following HdmX and Hdm2
knockdown (Figure 7).
Within the list of
downregulated genes were a set of genes that encode
proteins involved in G1-S phase transition, the majority
of which were known E2F1 regulated genes. It is
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Figure 4. GeneChip expression of 13 known p53‐
regulated genes that were induced by knockdown of
either siHdmX or siHdm2. Y‐axis represents the average
fold change (log2) for each of the genes in the indicated siRNA
transfections relative to siCon (X‐axis, conditions labeled at the
top of the chart).
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Here we have employed RNAi approaches and DNA
microarrays to better understand the activation of p53 in
cells overexpressing Hdm2 and HdmX. In MCF7 cells
a growth arrest with no detectable apoptosis was
observed following knockdown of either Hdm2 or
HdmX (Figure 2 and data not shown). While loss of
either HdmX or Hdm2 was sufficient to trigger an antiproliferative effect, the combined loss of both HdmX
and Hdm2 resulted in a more significant growth
inhibition.

DISCUSSION
As an essential tumor suppressor it is no surprise that
human tumors demonstrate a diverse array of genetic
mechanisms to inactivate p53 function. Central to this
present study are tumors where one or both of the
negative regulators of p53, Hdm2 and HdmX, are
overexpressed leading to loss of p53 activity. Previous
studies have focused on Hdm2 overexpression, where a
small molecule inhibitor Nutlin 3 has proven to activate
wild-type p53 in cell lines with elevated Hdm2,
triggering apoptosis when combined with genotoxic
agents that do not function as anti-mitotics [44].
Unfortunately, Nutlins have not proven as effective in
tumors where HdmX is overexpressed [18, 45-47],
suggesting the need for additional approaches aimed at
blocking the HdmX:p53 association particularly given
the recent observation of HdmX overexpression in
retinoblastoma [48].

Figure 6. GeneChip expression of 13 reported E2F1‐
regulated genes that were repressed by knockdown of
either siHdmX or siHdm2. Y‐axis represents the average
fold change (log2) for each of the genes in the indicated siRNA
transfections relative to siCon (X‐axis, conditions labeled at the
top of the chart).

Even though this RNAi approach appears to activate
p53 without triggering its phosphorylation (data not
shown), the loss of either HdmX or Hdm2 did
effectively sensitize the cells to doxorubicin with the
loss of both Hdm2 and HdmX being most sensitive to
DNA damage (Figure 3). Surprisingly our results
showed only a modest elevation of endogenous p53
levels following loss of HdmX and Hdm2 (Figure 1).
This result maybe unique to MCF7 cells which harbor
elevated Hdm2 and HdmX, in contrast to most tumor
cell lines with wild-type p53 that possessed only
elevated Hdm2 (Figure 1A). Consistent with the need
for only one negative regulator to be elevated 65% of
retinoblastoma tumors overexpress HdmX and possess
wild-type p53 [48]. Based on our previous HdmX
overexpression studies [10] we would predict that the
overexpression of HdmX might inhibit Hdm2
degradation of p53 in MCF7 cells and thus could
explain why modulating Hdm2 levels in MCF7 cells has
no dramatic effect on p53 levels.

Figure 5. RT‐qPCR validation of siRNA knockdown in
MCF7 cells. (A) The hdmX, hdm2, and p21 mRNA expression
relative to siCon (non‐targeting siRNA) is shown. The p21
transcript is induced following loss of HdmX or Hdm2, and
synergistically induced following loss of both HdmX and Hdm2.
(B) BTG2, ACTA2, and NOXA mRNA expression relative to
untransfected control (Con). The p53 target genes, BTG2 and
ACTA2, are induced by loss of HdmX and/or Hdm2, while the
expression of the proapoptotic gene, NOXA, is not altered.
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The DNA microarray experiment directly tested
whether HdmX or Hdm2 knockdown triggered an
increase in p53-regulated genes. While 394 genes were

94

AGING, January 2009, Vol.1 No.1

significantly altered by either HdmX or Hdm2
knockdown (Table 1), only a small group was
previously identified p53 targets (Figure 4). A few of
the remaining genes induced by HdmX or Hdm2 loss
are likely novel p53 regulated genes (S. Berberich,
personal communication) but most probably represent
downstream effects of the cell cycle arrest induced by
p53. Within the 13 identified p53 target genes it is
noteworthy that only one apoptotic gene (Fas) was
found activated by loss of either HdmX or Hdm2. Upon
careful examination of 16 known p53 pro-apoptotic
genes we found that several of them were repressed
following p53 knockdown, suggesting that their failure
to be induced by loss of HdmX or Hdm2 was not a celltype specific phenotype. Rather, we propose that the
non-genotoxic release of p53 from Hdm2 of HdmX
results in a preferential activation of growth arrest target
genes, like p21 (Figure 5). This model is consistent
with recent work suggesting that p53 promoter selection
is dependent on its phosphorylation [49].

While this report focused on genes commonly regulated
by HdmX and Hdm2, it is worth mentioning that within
genes uniquely regulated by either HdmX or Hdm2 we
did not observe any additional p53 regulated genes (M.
Markey, personal communication). The common
biological effects of HdmX or Hdm2-loss and
significant overlap of gene expression patterns are in
contrast to recent in vivo studies where the knockout of
Mdm2 or MdmX in adult mouse tissues lead to nonoverlapping roles in regards to regulating p53 activity
[51]. We believe these findings point to either
differences in cell culture verses tissue studies or more
likely represent a significant departure in the roles that
Hdm2 and HdmX play when expressed at physiological
levels compared to the elevated levels in tumor cells.
Finally these studies demonstrate that non-genotoxic
activation of p53 by knockdown of its inhibitors Hdm2
and HdmX leads to the induction of genes involved in
cell-cycle arrest, as well as repression of genes along
the E2F/Rb pathway that promote cell cycle entry.
These alterations in gene expression resulted in a
decreased population of proliferative cells without
necessarily increasing apoptosis. A non-genotoxic
activation of p53 is one possible mechanism for the
reduction in cellular proliferation observed during
aging. This further underscores the critical importance
of tumor suppressor activation in senescence and
organismal aging.
MATERIALS AND METHODS
Cell lines, antibodies, siRNA and chemotherapeutic
agents. The human breast tumor cell line MCF7 was
grown in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% bovine growth serum (BGS),
and 10 µg/ml gentamicin unless otherwise indicated.
HdmX polyclonal antibody (Bethyl Laboratories, Inc.),
p21 polyclonal antibody C-19 (Santa Cruz
Biotechnology, Inc.), p53 monoclonal antibody Ab-6
(Oncogene), Hdm2 monoclonal antibody SMP-14
(Santa Cruz Biotechnology, Inc.) and beta-actin
monoclonal antibody (Sigma, Inc.) were used as
indicated. A phosphorylation-specific p53 polyclonal
antibody kit (Cell Signaling Technology, Inc.) was
utilized per manufacturer’s protocol.
Horseradish
peroxidase (HRP)-conjugated anti-mouse or anti-rabbit
secondary antibodies (Promega) were used with Super
Signal substrate (Pierce) for chemiluminescence
detection of proteins.
siGENOME duplex RNA
targeting mRNA from hdmX, hdm2, or p53, and a nontargeting control siRNA were obtained from
Dharmacon Research, Inc. and siRNA transfection was
performed using Oligofectamine or Lipofectamine 2000
(Invitrogen) as described below. Doxorubicin hydro-

Figure 7. Repression of E2F1‐regulated genes by Hdm2
or HdmX knockdown is blocked by concurrent
knockdown of p21. MCF7 cells were transfected with the
indicated siRNA combinations. Twenty‐four hours later, RNA
was isolated and subjected to RT‐qPCR to quantify expression
of CCNA2, p21 and E2F1 after normalization to GAPDH.
Expression levels (Y‐axis) were relative to siCon and reported
as RQ values. Error bars represent the 95% confidence
interval of the relative expression.

Another interesting finding within the microarray data
was a subgroup of genes that were repressed upon
HdmX and Hdm2 knockdown and could be classified as
known E2F-regulated genes. Other groups have noted
that p53 activation of p21 could lead to the repression of
TERT [42] or Chk2 [41], known E2F-target genes, and
another group recently reported similar findings using
microarray assays [50].
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chloride (Tocris Bioscience) was prepared as a 5 mg/ml
stock solution in water.

Quantitative RT-pPCR. Cells were lysed directly in the
culture dish and total RNA was isolated using the
RNeasy kit (Qiagen) according to manufacturer’s
protocol. The RNA was quantified by spectrophotometer reading at 260 nm, and 1 µg RNA was reverse
transcribed with random hexamers to create cDNA
using the TaqMan Reverse transcription kit (Applied
Biosystems). Quantitative PCR was performed in a 96well micro titer plate format on an ABI Prism 7900HT
sequence detection system using 1 µl cDNA, TaqMan
Universal PCR master mix and Assay-on-Demand Gene
Expression products (Applied Biosystems) specific for
genes of interest. Each cDNA sample was analyzed in
triplicate and fold change relative to control was
calculated based on a PCR efficiency of two and
normalized to GAPDH (endogenous control) RNA
levels. Average fold change and standard deviation
were obtained from 2-3 biological replicate samples per
treatment assayed in triplicate.

siRNA transfection. Cells were seeded at 200,000 cells
per well in 6-well plates (for RNA isolation), or at
700,000 cells per 6-cm dish (for protein extraction) in
antibiotic free DMEM containing 1% BGS in a small
volume. Cells were reverse transfected with 100 nM
siRNA (Dharmacon Research, Inc.) at time of seeding
using Lipofectamine 2000 (Invitrogen). After a five
hour incubation, the media was removed and cells were
refed with DMEM containing 10% BGS. Twenty hours
later, the cells were transfected again with 100 nM
siRNA in a small volume of serum free media using
Oligofectamine (Invitrogen).
After a four-hour
incubation, an equal volume of DMEM containing 20%
BGS was added to each well or dish without removing
the transfection mixture. Total RNA was isolated 24
hours post siRNA transfection and protein was
extracted at 48 hours post siRNA unless otherwise
indicated.

Western blot analysis. Frozen cells were lysed in an
aqueous extraction buffer composed of 120 mM NaCl,
50 mM Tris-HCl (pH 8.0), 5 mM EGTA, 1 mM EDTA,
5 mM NaPPi, 10 mM NaF, 30 mM paranitrophenylphosphate, 1 mM Benzamidine, 0.1% NP-40
(Ipegal Ca-630), 0.2 mM PMSF, and 1% protease
inhibitor cocktail (Sigma), and soluble protein was
recovered by centrifugation. Protein concentration was
determined using Bradford reagent (Bio-Rad), and
proteins were resolved on a sodium dodecyl sulfate10% polyacrylamide gel followed by transfer of
proteins to a polyvinylidene difluoride membrane
(Millipore) using a Transblot system (Bio-Rad).
Immunoblotting was performed as previously described
[52] using appropriate primary antibodies at 1:10001:10,000 dilution and secondary antibodies (goat antimouse or goat anti-rabbit HRP-conjugated, Promega) at
1:5000-1:10,000 dilution.
Blots were exposed to
chemiluminescent reagent (Pierce) and protein was
visualized on a FUJIFILM LAS-3000 image reader.

Analysis of Affymetrix GeneChips. The Affymetrix
HG-U133 plus 2.0 GeneChips containing probe sets
detecting over 54,000 transcripts were used in this study
and each transfection condition was performed in
triplicate. GeneChip cel files were imported into
GeneSpring GX and preprocessed by GCRMA.
Measurements less than 0.01 were then set to 0.01, and
each chip was normalized to the 50th percentile of the
measurements taken from that chip. Extra background
correction was never applied.
Each gene was
normalized to the median of the measurements for that
gene, and then to the median of that gene’s expression
in the siCon condition.
Initially all genes were filtered in GeneSpring GX first
by Welch ANOVA to find expression changes based on
siRNA treatment, using a p-value cut off of 0.05 and the
Benjamini and Hochberg False Discovery Rate as a
multiple testing correction. The cross-gene error model
was active and based on replicates. From this list, genes
were removed which varied between the mock and
siCon treatments by 1.5 fold with a p-value < 0.05.
Next, lists of genes with expression changes of 1.5 fold
and a p-value < 0.05 were then made for siHdm2 versus
siCon and siHdmX versus siCon. We then eliminated
all but the union between these two lists. One gene that
was repressed in the siHdm2 condition but upregulated
in the siHdmX condition (encoding hypothetical protein
MGC5370) was manually removed. Finally, genes that
were not changed 1.5 fold with a p-value of <0.05
between the siHdmX and siHdmX + sip53 conditions
were removed leaving a total of 394 selected genes.
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Colony formation and cell viability assays. Twenty-four
hours after the second siRNA transfection, the cells
were trypsinized, counted and seeded at 500 cells per
well in 6-well plates for the colony formation assay.
The cells were allowed to grow for ten days, and then
the colonies were fixed and stained in 1% crystal violet
in 70% methanol. The cell viability assays were
performed in 96-well plates using either CellQuantiBlue™ Reagent (BioAssay Systems) according to
manufacturer’s protocol or by staining the cells with
crystal violet, extracting the stain in 10% acetic acid,
and then reading absorbance at 590 nm. Again, cells
were trypsinized after the second siRNA transfection,
counted and seeded at 20,000 cells per well. Cell
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